Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$180.96 USD

180.96
830,357

+2.38 (1.33%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock

Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates

Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ICLR vs. CRL: Which Stock Is the Better Value Option?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

ICLR or CRL: Which Is the Better Value Stock Right Now?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

Charles River (CRL) Forges Collaboration With Wheeler Bio

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.